The Glucagon Paradox in Next-Generation Incretin Therapy: GLP-1, GIP, and Glucagon Receptor Co-Agonism

The Glucagon Paradox in Next-Generation Incretin Therapy: How GLP-1, GIP, and Glucagon Receptor Co-Agonism May Amplify Weight Loss Despite Glucagon’s Hyperglycemic Biology D. Mcauley Abstract The development of dual and triple incretin-based receptor agonists represents a major advance in the pharmacologic treatment of obesity, type

Revolutionizing Diabetes Monitoring: Beyond A1C to Continuous Metabolic Profiling

Revolutionizing Diabetes Monitoring Beyond A1C to Continuous Metabolic Profiling Review Abstract Diabetes mellitus remains one of the most prevalent and challenging chronic diseases worldwide, affecting hundreds of millions of individuals and contributing significantly to cardiovascular disease, kidney failure, blindness, neuropathy, and premature mortality. Effective diabetes management

Managing Diabetes in the Age of Continuous Glucose Monitoring (CGM): How Practice is Changing

Managing Diabetes in the Age of Continuous Glucose Monitoring (CGM) How Practice is Changing Review Abstract The integration of continuous glucose monitoring technology into diabetes management has significantly reshaped clinical practice over the past decade. Continuous glucose monitoring systems provide real time, dynamic assessment of interstitial glucose

Type 2 Diabetes Mellitus: Cellular Mechanisms, Reductionist Pitfalls, and Evidence-Based Prevention

Type 2 Diabetes Mellitus as a Multifactorial Cardiometabolic Disease: Cellular Mechanisms, Reductionist Pitfalls, and Evidence-Based Prevention Narrative Review Abstract Type 2 diabetes mellitus (T2DM) is a progressive, heterogeneous, multi-organ metabolic disease characterized by chronic hyperglycemia arising from inadequate insulin secretion relative to metabolic demand, usually

Glucagon-Like Peptide-1 Receptor Agonists and Human Fertility

Glucagon-Like Peptide-1 Receptor Agonists and Human Fertility: Mechanisms, Evidence, and Clinical Implications Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well established for the treatment of type 2 diabetes mellitus and obesity. Increasingly, reports suggest a possible association between GLP-1 RA use and

The Glucagon Paradox in Next-Generation Incretin Therapy: GLP-1, GIP, and Glucagon Receptor Co-Agonism